| 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 相 | | | --- | --- | --- | --- | --- | --- | --- | | | 플 | 原因 | 股份數目 | | (請參閱上述*註 | 有投票權股 (日 / 月 / 年) 福 | | | | | | | | 份自分比 | | | | | | | | ( % ) | | CS20250916E00196 | 4,174,400(L) 易方达基金管理有限公司 | 1201(L) | | HKD 44.3362 | 12,370,300(L) | 10.05(L) 11/09/2025 | 泰格医药(3347.HK)现跌5.13%报46.2港元，暂成交2.3亿港元，最新市值397.8亿港元。联交所最新权益披露资料显示，泰格医药于9月11日遭易方达基金管理 有限公司在场内以每股均价44.3362港元减持417.44万股，涉资约1.85亿港元。减持后，其持股比例由13.44%下降至10.05%。(格隆汇) ...

Group 1 - The core point of the article is that E Fund Management Co., Ltd. has reduced its stake in Tiger Med (03347.HK) by selling 4.1744 million shares at an average price of HKD 44.3362 per share, amounting to approximately HKD 185 million [1][2] - After the reduction, E Fund's total shareholding in Tiger Med is now 12.3703 million shares, which represents a decrease in ownership from 13.44% to 10.05% [1][2]

香港联交所最新资料显示，9月11日，易方达基金减持泰格医药(03347)417.44万股，每股作价44.3362港 元，总金额约为1.85亿港元。减持后最新持股数目为1237.03万股，持股比例为10.05%。 ...

智通财经APP获悉，香港联交所最新资料显示，9月11日，易方达基金减持泰格医药(03347)417.44万 股，每股作价44.3362港元，总金额约为1.85亿港元。减持后最新持股数目为1237.03万股，持股比例为 10.05%。 ...

Core Viewpoint - Tiger Med's stock price has experienced fluctuations, with a year-to-date increase of 11.41% but a recent decline of 6.40% over the past five trading days [1] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1] - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] - The revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1] Financial Performance - As of June 30, 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed in the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 4.14% to 51,500 [2] - The top circulating shareholders include China Europe Medical Health Mixed A, holding 27.634 million shares, and Hong Kong Central Clearing Limited, holding 23.266 million shares, with respective changes in holdings noted [3]

Company Overview - Tiger Med is a clinical research service provider based in Hangzhou, China, specializing in I-IV phase clinical trials, data management, and medical testing services [1][2] - The company was established on December 15, 2004, and went public on August 17, 2012 [1] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has distributed a total of 2.46 billion yuan in dividends since its A-share listing, with 1.15 billion yuan distributed over the last three years [3] Stock Performance - As of September 15, Tiger Med's stock price increased by 2.02% to 62.24 yuan per share, with a market capitalization of 53.59 billion yuan [1] - Year-to-date, the stock has risen by 14.58%, but it has seen a decline of 7.37% over the last five trading days and 10.45% over the last 20 days [1] Shareholder Structure - As of June 30, 2025, Tiger Med had 51,500 shareholders, a decrease of 4.14% from the previous period [2] - The top shareholders include various funds, with notable changes in holdings among major institutional investors [3]

Group 1 - The core point of the news is that Tiger Med's stock has experienced a decline, with a cumulative drop of 9.2% over the last four days, closing at 61.01 yuan per share on September 12, with a total market capitalization of 52.531 billion yuan [1] - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV clinical trials, data management, and other related services [1] - The company's main revenue sources include clinical trial-related services and laboratory services (52.60%), clinical trial technical services (45.21%), and other services (2.19%) [1] Group 2 - Morgan Fund holds a position in Tiger Med through the Morgan CSI Innovative Drug Industry ETF (560900), which reduced its holdings by 3,000 shares in the second quarter, now holding 18,100 shares, accounting for 2.76% of the fund's net value [2] - The Morgan CSI Innovative Drug Industry ETF has a total scale of 34.9084 million, with a year-to-date return of 40.82% and a one-year return of 60.71% [2] - The fund manager, Mao Shichao, has been in position for 5 years and 128 days, with the fund's best return during this period being 56.22% and the worst being -24.75% [3]

Market Overview - The Hong Kong stock market experienced a collective pullback, with the Hang Seng Index down 0.43% to 26,086.32 points, the Tech Index down 0.24% to 5,888.77 points, and the National Enterprises Index down 0.73% to 9,260.25 points [1][2]. Semiconductor Sector - The semiconductor sector led the market with notable gains, including InnoCare (02577.HK) up 9.25%, SMIC (00981.HK) up 4.97%, and Shanghai Fudan (01385.HK) up 5.37% [4][5]. - TSMC reported a revenue of NT$335.77 billion for August 2025, marking a year-on-year increase of 33.8% and a quarter-on-quarter increase of 3.9%, boosting market expectations for AI infrastructure development [6]. Telecommunications Equipment - Telecommunications equipment stocks also saw strong performance, with ZTE (00763.HK) up 7.50%, and China Tower (00788.HK) up 3.19% [8]. Nonferrous Metals - Nonferrous metal stocks were buoyed by interest rate cut expectations, with Jinli Permanent Magnet (06680.HK) up 6.04% and Luoyang Molybdenum (03993.HK) up 4.79% [9][10]. - Minsheng Securities noted that industrial metal supply remains constrained while domestic demand remains resilient, suggesting a potential upward trend in metal prices [11]. Cement Sector - The cement sector benefited from price increases, with Huaxin Cement (06655.HK) up 4.94% and China National Building Material (03323.HK) up 3.38% [12][13]. - Research indicated that cement prices in the Pearl River Delta region are expected to rebound due to seasonal demand and reduced supply [14]. Pharmaceutical Sector - Pharmaceutical stocks faced downward pressure, with Tigermed (03347.HK) down 9.36% and Zai Lab (06160.HK) down 5.87% [15][16]. - Market rumors about potential restrictions on innovative drugs from China to the U.S. have not significantly altered long-term expectations for these companies [17][18]. New Consumption Sector - New consumption stocks showed weakness, with Maogeping (01318.HK) down 4.73% and Laopu Gold (06181.HK) down 3.51% [19][20]. - Despite the current underperformance, institutions remain optimistic about the growth potential of new consumption companies, driven by changing consumer behaviors among the Z generation [21]. Individual Stock Movements - China Gold International (02099.HK) rose 2.70% amid increasing expectations for U.S. interest rate cuts [22]. - Tenghong Precision (06088.HK) surged 12.79% following the announcement of new Apple products, including new iPhones and AirPods [23][24].

Core Viewpoint - The Hong Kong pharmaceutical sector experienced significant declines, with major companies facing substantial stock price drops on September 11. Company Performance - Tigermed (03347.HK) saw a decline of 14.06% - Viva Biotech (01873.HK) dropped by 11.85% - Kanglong Chemical (03759.HK) fell by 10% - Zai Lab (06172.HK) decreased by 8.26% [1]

Company Overview - Tiger Med is located in Hangzhou, Zhejiang Province, and was established on December 15, 2004, with its IPO on August 17, 2012 [1] - The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products, covering I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has cumulatively distributed 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3] Stock Performance - As of September 9, Tiger Med's stock price was 65.83 yuan per share, with a market capitalization of 56.681 billion yuan [1] - Year-to-date, the stock price has increased by 21.18%, but it has seen a decline of 0.63% over the last five trading days and 1.78% over the last twenty days [1] Shareholder Information - As of June 30, 2025, the number of shareholders was 51,500, a decrease of 4.14% from the previous period [2] - The top ten circulating shareholders include notable funds, with changes in their holdings indicating varying levels of investment interest [3]